UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000018202
Receipt number R000021051
Scientific Title A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Locally Advanced and Metastatic Breast Cancer(Study of Perjeta re-treatment for clinical outcomes)
Date of disclosure of the study information 2015/07/06
Last modified on 2021/07/15 15:43:30

No. Disposal Last modified on Item of update
1 Insert 2015/07/06 00:51:58
2 Update 2016/02/17 13:30:18 Interventions/Control_1
Interventions/Control_1
Interventions/Control_2
Interventions/Control_2
3 Update 2016/07/06 09:24:05 Name of primary person or sponsor
Organization
4 Update 2017/04/05 19:04:36 Interventions/Control_1
Interventions/Control_1
Interventions/Control_2
Interventions/Control_2
5 Update 2018/08/23 17:44:47 Public title
6 Update 2018/08/24 10:10:34 UMIN ID1
7 Update 2019/09/05 15:50:43 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Organization
Zip code
Address
Address

Last name of contact person

Last name of contact person
Zip code
Address
Address
Organization
Organization
Address
Address
Tel
Email
8 Update 2019/09/05 16:02:23 Recruitment status
Date of IRB
Anticipated trial start date
9 Update 2019/09/05 16:05:19 Number of participants that the trial has enrolled
10 Update 2020/01/29 18:39:19 Organization
Organization
Division name
Organization
Organization
Institute
11 Update 2020/01/29 18:48:10 Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
12 Update 2021/07/02 20:30:02
Last name of contact person

Last name of contact person
Name of person sending information
Name of person sending information
13 Update 2021/07/15 15:43:30 Homepage URL